These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 17014387)

  • 1. Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy.
    Ieiri I; Takane H; Hirota T; Otsubo K; Higuchi S
    Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):651-74. PubMed ID: 17014387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
    Ieiri I; Higuchi S; Sugiyama Y
    Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Species differences in drug transporters and implications for translating preclinical findings to humans.
    Chu X; Bleasby K; Evers R
    Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):237-52. PubMed ID: 23256482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of transporters in hepatic drug disposition].
    Gao CY; Chen XY; Zhong DF
    Yao Xue Xue Bao; 2012 May; 47(5):565-72. PubMed ID: 22811997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of membrane transporters: a review of current approaches.
    Sissung TM; Gardner ER; Gao R; Figg WD
    Methods Mol Biol; 2008; 448():41-62. PubMed ID: 18370230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.
    Bruhn O; Cascorbi I
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1337-54. PubMed ID: 25162314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs.
    Maeda K; Sugiyama Y
    Drug Metab Pharmacokinet; 2008; 23(4):223-35. PubMed ID: 18762709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of genetic polymorphisms in drug transporters for pharmacotherapy.
    Kerb R
    Cancer Lett; 2006 Mar; 234(1):4-33. PubMed ID: 16504381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.
    Hua WJ; Hua WX; Fang HJ
    Cardiovasc Ther; 2012 Oct; 30(5):e234-41. PubMed ID: 21884024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The MDR1 (ABCB1) gene polymorphism and its clinical implications.
    Ieiri I; Takane H; Otsubo K
    Clin Pharmacokinet; 2004; 43(9):553-76. PubMed ID: 15217301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members.
    Seithel A; Glaeser H; Fromm MF; König J
    Expert Opin Drug Metab Toxicol; 2008 Jan; 4(1):51-64. PubMed ID: 18370858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International Transporter Consortium commentary on clinically important transporter polymorphisms.
    Giacomini KM; Balimane PV; Cho SK; Eadon M; Edeki T; Hillgren KM; Huang SM; Sugiyama Y; Weitz D; Wen Y; Xia CQ; Yee SW; Zimdahl H; Niemi M;
    Clin Pharmacol Ther; 2013 Jul; 94(1):23-6. PubMed ID: 23778707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RT-PCR analysis of ABC, SLC and SLCO drug transporters in human lung epithelial cell models.
    Endter S; Francombe D; Ehrhardt C; Gumbleton M
    J Pharm Pharmacol; 2009 May; 61(5):583-91. PubMed ID: 19405996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of membrane transporters: an update on current approaches.
    Sissung TM; Baum CE; Kirkland CT; Gao R; Gardner ER; Figg WD
    Mol Biotechnol; 2010 Feb; 44(2):152-67. PubMed ID: 19950006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
    Ebner T; Ishiguro N; Taub ME
    J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of OATP transporters in the disposition of drugs.
    Niemi M
    Pharmacogenomics; 2007 Jul; 8(7):787-802. PubMed ID: 18240907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomics of the OATP and OAT families.
    Marzolini C; Tirona RG; Kim RB
    Pharmacogenomics; 2004 Apr; 5(3):273-82. PubMed ID: 15102542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of intestinal absorption.
    Nakamura T; Yamamori M; Sakaeda T
    Curr Drug Deliv; 2008 Jul; 5(3):153-69. PubMed ID: 18673259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine and metabolic regulation of renal drug transporters.
    Yacovino LL; Aleksunes LM
    J Biochem Mol Toxicol; 2012 Oct; 26(10):407-21. PubMed ID: 22933250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia.
    Polillo M; Galimberti S; Baratè C; Petrini M; Danesi R; Di Paolo A
    Int J Mol Sci; 2015 Sep; 16(9):22811-29. PubMed ID: 26402671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.